LEXINGTON, Mass., Aug. 28, 2018 /PRNewswire/ -- Curis, Inc.
(NASDAQ: CRIS), a biotechnology company focused on the development
and commercialization of innovative and effective therapeutics for
the treatment of cancer, today announced that the Company will
present at the Baird 2018 Global Healthcare Conference on
Wednesday, September 5 at
2:35-3:05 PM in Session III - Empire
Ballroom B, Mezzanine Level of the InterContinental New York
Barclay in New York.
The presentation will be held using a fireside-chat format in
which Ali Fattaey, Ph.D. President
and Chief Executive Officer, will provide a brief overview of the
Company's pipeline of drug candidates and business strategy, after
which an equity analyst will moderate a question and answer
session.
A live webcast of the presentation will be available by visiting
the investors section of Curis' website
http://investors.curis.com/events-and-presentations.
A replay of the webcast will be archived on the website for 30
days following the presentation.
About Curis
Curis is a biotechnology company focused
on the development and commercialization of innovative therapeutics
for the treatment of cancer, including fimepinostat, which is being
investigated in clinical studies in patients with DLBCL and solid
tumors. Curis is also engaged in a collaboration with Aurigene in
the areas of immuno-oncology and precision oncology. As part of
this collaboration, Curis has exclusive licenses to oral small
molecule antagonists of immune checkpoints including, the
PDL1/VISTA antagonist CA-170, and the PDL1/TIM3 antagonist CA-327,
as well as the IRAK4 kinase inhibitor, CA-4948. CA-170 is currently
undergoing testing in a Phase 1 trial in patients with advanced
solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene. CA-4948 is
currently undergoing testing in a Phase 1 trial in patients with
non-Hodgkin lymphoma. Curis is also party to a collaboration with
Genentech, a member of the Roche Group, under which Genentech and
Roche are commercializing Erivedge® for the treatment of advanced
basal cell carcinoma. For more information, visit Curis's website
at www.curis.com.
Cautionary Note Regarding Forward-Looking
Statements:
This press release contains forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995, including without limitation
statements regarding any expectations of revenue, expenses,
earnings or losses from operations, or other financial results,
statements with respect to the plans, strategies and objectives of
management for future operations, the potential for the Company's
proprietary drug candidates, including fimepinostat, CA-170, and
CA-4948, the potential advantages and benefits of small molecule
checkpoint antagonists, the Company's plans and expectations for
the collaboration with Aurigene, including its plans to discover
and develop multiple first-in-class oral, small molecule checkpoint
antagonists for the treatment of patients with cancer, and the
Company's plans to advance its development programs, including the
timing of IND filings and the Company's plans for fimepinostat.
Forward-looking statements may contain the words "believes,"
"expects," "anticipates," "plans," "intends," "seeks," "estimates,"
"assumes," "will," "may," "could" or similar expressions. These
forward-looking statements are not guarantees of future performance
and involve risks, uncertainties, assumptions and other important
factors that may cause actual results to be materially different
from those indicated by such forward-looking statements. For
example, Curis may experience adverse results, delays and/or
failures in its drug development programs and may not be able to
successfully advance the development of its drug candidates in the
time frames it projects, if at all. Curis's drug candidates may
cause unexpected toxicities, fail to demonstrate sufficient safety
and efficacy in clinical studies and/or may never achieve the
requisite regulatory approvals needed for commercialization.
Favorable results seen in preclinical studies and early clinical
trials of Curis's drug candidates may not be replicated in later
trials. There can be no guarantee that the collaboration agreement
with Aurigene will continue for its full term, that Curis or
Aurigene will each maintain the financial and other resources
necessary to continue financing its portion of the research,
development and commercialization costs, or that the parties will
successfully discover, develop or commercialize drug candidates
under the collaboration. Regulatory authorities may determine to
delay or restrict Genentech's and/or Roche's ability to continue to
develop or commercialize Erivedge in BCC. Erivedge may not
demonstrate sufficient or any activity to merit its further
development in disease indications other than BCC. Competing drugs
may be developed that are superior to Erivedge. Curis faces risks
relating to its wholly-owned subsidiary's royalty-collateralized
loan transaction, including the risk that it may not receive
sufficient levels of royalty revenue from sales of Erivedge to
satisfy the debt obligation or may otherwise lose its rights to
royalties and royalty-related payments as a result of a foreclosure
of the loan. Curis will require substantial additional capital to
fund its business and such capital may not be available on
reasonable terms, or at all. Curis faces substantial competition.
Curis also faces risks relating to potential adverse decisions made
by the FDA and other regulatory authorities, investigational review
boards, and publication review bodies. Curis may not obtain or
maintain necessary patent protection and could become involved in
expensive and time-consuming patent litigation and interference
proceedings. Unstable market and economic conditions and unplanned
expenses may adversely affect Curis's financial conditions and its
ability to access the substantial additional capital needed to fund
the growth of its business. Important factors that may cause or
contribute to such differences include the factors set forth under
the caption "Risk Factors" in our most recent Form 10-K and Form
10-Q and the factors that are discussed in other filings that we
periodically make with the Securities and Exchange Commission
("SEC"). In addition, any forward-looking statements represent the
views of Curis only as of today and should not be relied upon as
representing Curis's views as of any subsequent date. Curis
disclaims any intention or obligation to update any of the
forward-looking statements after the date of this press release
whether as a result of new information, future events or otherwise,
except as may be required by law.
View original
content:http://www.prnewswire.com/news-releases/curis-to-present-at-the-baird-2018-global-healthcare-conference-300703611.html
SOURCE Curis, Inc.